Aquinox Pharmaceuticals (AQXP): Dumped By Big PharmasMani
Johnson & Johnson and Pfizer both pruned their holdings in Aquinox Pharmaceuticals following the recent run-up in its shares.
Aquinox Pharmaceuticals (AQXP) soared recently after the company announced positive results from secondary endpoints from its Phase 2 LEADERSHIP trial with AQX-1125 in patients with bladder pain syndrome/interstitial cystitis (BPS/IC).
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.